Oruka Therapeutics (ORKA) Interest & Investment Income (2010 - 2024)
Oruka Therapeutics' quarterly Interest & Investment Income came in at $444000.0 in Q2 2024, down 9.94% year-on-year from $493000.0 in Q3 2023, and down 6.13% quarter-over-quarter from $473000.0 in Q1 2024.
Oruka Therapeutics has reported Interest & Investment Income for 15 years, with the latest figure at $444000.0 in Q2 2024.
- For the quarter ending Q2 2024, Interest & Investment Income fell 9.94% year-over-year to $444000.0; the trailing twelve-month figure through Jun 2024 stood at $1.9 million (up 25.47% YoY), and the FY2023 full-year result was $2.0 million, up 189.93% from the prior year.
- Interest & Investment Income for Q2 2024 stood at $444000.0, down from $473000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $513000.0 in Q3 2023, with the low at $1000.0 in Q3 2020.
- Average Interest & Investment Income over 5 years is $199444.4, with a median of $48000.0 recorded in 2020.
- Year-over-year, Interest & Investment Income tumbled 98.0% in 2020 and soared 9250.0% in 2022.
- Tracing ORKA's Interest & Investment Income over 5 years: stood at $1000.0 in 2020, then soared by 300.0% to $4000.0 in 2021, then soared by 9250.0% to $374000.0 in 2022, then soared by 33.96% to $501000.0 in 2023, then dropped by 11.38% to $444000.0 in 2024.
- The last three Interest & Investment Income figures came in at $444000.0 (Q2 2024), $473000.0 (Q1 2024), and $501000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 444,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Dec 31, 2023 | 501,000.00 |
| Sep 30, 2023 | 513,000.00 |
| Jun 30, 2023 | 493,000.00 |
| Mar 31, 2023 | 450,000.00 |
| Dec 31, 2022 | 374,000.00 |
| Sep 30, 2022 | 222,000.00 |
| Jun 30, 2022 | 72,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 4,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | 24,000.00 |
| Dec 31, 2019 | 36,000.00 |
| Sep 30, 2019 | 50,000.00 |
| Jun 30, 2019 | 48,000.00 |
| Mar 31, 2019 | 38,000.00 |
| Dec 31, 2018 | 38,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Jun 30, 2018 | 43,000.00 |
| Mar 31, 2018 | 41,000.00 |
| Dec 31, 2017 | 39,000.00 |
| Sep 30, 2017 | 44,000.00 |
| Jun 30, 2017 | 39,000.00 |
| Mar 31, 2017 | 45,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Sep 30, 2016 | 53,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Mar 31, 2016 | 21,000.00 |
| Dec 31, 2015 | 7,000.00 |
| Sep 30, 2015 | 4,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 1,000.00 |
| Dec 31, 2014 | 1,000.00 |
| Sep 30, 2014 | 2,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 2,000.00 |
| Dec 31, 2013 | 2,000.00 |
| Sep 30, 2013 | 2,000.00 |
| Jun 30, 2013 | 1,000.00 |
| Dec 31, 2012 | -1,000.00 |
| Sep 30, 2012 | 2,000.00 |
| Jun 30, 2012 | 1,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Mar 31, 2011 | 1,000.00 |
| Dec 31, 2010 | 758,000.00 |
| Sep 30, 2010 | 3,000.00 |
| Jun 30, 2010 | 1,000.00 |